ADVAIR DISKUS
Total Payments
$229,657
Transactions
104
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $229,657 | 104 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $228,732 | 102 | 99.6% |
| Consulting Fee | $925.00 | 2 | 0.4% |
Payments by Type
Research
$228,732
102 transactions
General
$925.00
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 6 month safety and benefit study of inhaled fluticasone propionate salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4 11 years old with persistent asthma | GlaxoSmithKline, LLC. | $137,180 | 0 |
| SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma | GlaxoSmithKline, LLC. | $66,177 | 0 |
| Expansion of the COPD At Risk Module in Multiple States | GlaxoSmithKline, LLC. | $25,375 | 0 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $229,657
Product Information
- Type Drug
- Total Payments $229,657
- Total Doctors 2
- Transactions 104
About ADVAIR DISKUS
ADVAIR DISKUS is a drug associated with $229,657 in payments to 2 healthcare providers, recorded across 104 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2017. In 2017, $229,657 was paid across 104 transactions to 2 doctors.
The most common payment nature for ADVAIR DISKUS is "Unspecified" ($228,732, 99.6% of total).
ADVAIR DISKUS is associated with 3 research studies, including "A 6 month safety and benefit study of inhaled fluticasone propionate salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4 11 years old with persistent asthma" ($137,180).